IL4 and allergic disease: In addition, TMC-264 selectively inhibited interleukin-4 (IL-4) signaling by interfering with phosphorylation of the signal transducer and activator of transcription 6 (STAT6), as well as binding of the phosphorylated STAT6 to the recognition sequence, so it might be an inhibitor of IL-4 signaling for treatment of allergic diseases [15].